412 related articles for article (PubMed ID: 17303976)
21. Peroxisome proliferator-activated receptors and acute lung injury.
Cuzzocrea S
Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
[TBL] [Abstract][Full Text] [Related]
22. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes.
Blaschke F; Caglayan E; Hsueh WA
Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586
[TBL] [Abstract][Full Text] [Related]
23. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears.
Mao Z; Ong AC
Nephron Clin Pract; 2009; 112(4):c230-41. PubMed ID: 19546582
[TBL] [Abstract][Full Text] [Related]
24. Type 2 diabetes, dyslipidemia, and vascular risk: rationale and evidence for correcting the lipid imbalance.
Carmena R
Am Heart J; 2005 Nov; 150(5):859-70. PubMed ID: 16290951
[TBL] [Abstract][Full Text] [Related]
25. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study].
Szymborska-Kajanek A; Strojek K
Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340
[No Abstract] [Full Text] [Related]
26. A novel peroxisome proliferator--activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys.
Ding SY; Tigno XT; Braileanu GT; Ito K; Hansen BC
Metabolism; 2007 Oct; 56(10):1334-9. PubMed ID: 17884441
[TBL] [Abstract][Full Text] [Related]
27. PPARs as therapeutic targets in cardiovascular disease.
van Bilsen M; van Nieuwenhoven FA
Expert Opin Ther Targets; 2010 Oct; 14(10):1029-45. PubMed ID: 20854178
[TBL] [Abstract][Full Text] [Related]
28. Alpha-alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor alpha and gamma.
Rau O; Syha Y; Zettl H; Kock M; Bock A; Schubert-Zsilavecz M
Arch Pharm (Weinheim); 2008 Mar; 341(3):191-5. PubMed ID: 18275039
[TBL] [Abstract][Full Text] [Related]
29. Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.
Nicholls SJ; Uno K
Diab Vasc Dis Res; 2012 Apr; 9(2):89-94. PubMed ID: 22407927
[TBL] [Abstract][Full Text] [Related]
30. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
[TBL] [Abstract][Full Text] [Related]
31. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
Matin A; Gavande N; Kim MS; Yang NX; Salam NK; Hanrahan JR; Roubin RH; Hibbs DE
J Med Chem; 2009 Nov; 52(21):6835-50. PubMed ID: 19807106
[TBL] [Abstract][Full Text] [Related]
32. Examining the safety of PPAR agonists - current trends and future prospects.
Bortolini M; Wright MB; Bopst M; Balas B
Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic potential of peroxisome proliferators--activated receptor-alpha/gamma dual agonist with alleviation of endoplasmic reticulum stress for the treatment of diabetes.
Han KL; Choi JS; Lee JY; Song J; Joe MK; Jung MH; Hwang JK
Diabetes; 2008 Mar; 57(3):737-45. PubMed ID: 18065517
[TBL] [Abstract][Full Text] [Related]
34. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
Gacka M; Adamiec R; Dobosz T; Szymaniec S; Bednarska-Chabowska D
Przegl Lek; 2004; 61(12):1436-9. PubMed ID: 15850344
[TBL] [Abstract][Full Text] [Related]
35. PPAR-gamma: therapeutic target for ischemic stroke.
Culman J; Zhao Y; Gohlke P; Herdegen T
Trends Pharmacol Sci; 2007 May; 28(5):244-9. PubMed ID: 17416424
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and evaluation of carbazole derivatives as PPAR alpha/gamma dual agonists and antioxidants.
Kumar R; Ramachandran U; Srinivasan K; Ramarao P; Raichur S; Chakrabarti R
Bioorg Med Chem; 2005 Jul; 13(13):4279-90. PubMed ID: 15869880
[TBL] [Abstract][Full Text] [Related]
38. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
Liu K; Xu L; Berger JP; Macnaul KL; Zhou G; Doebber TW; Forrest MJ; Moller DE; Jones AB
J Med Chem; 2005 Apr; 48(7):2262-5. PubMed ID: 15801817
[TBL] [Abstract][Full Text] [Related]
40. PPAR-gamma receptor agonists--a review of their role in diabetic management in Trinidad and Tobago.
Smith SI
Mol Cell Biochem; 2004 Aug; 263(1-2):189-210. PubMed ID: 15524180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]